Science + Pipeline

BXQ-350 is a novel sphingolipid metabolism modulator

being developed as a unique biologic for the treatment of solid tumors and neurological diseases

A pipeline in a product

As a modulator of sphingolipid metabolism, BXQ-350 has the potential to address unmet medical needs across a variety of tumor types and neurological diseases. Emerging evidence supports the opportunity for sphingolipid modulation to impact a broad range of indications.

Biologic (SapC)

BXQ-350 is composed of the multifunctional, sphingolipid activator Saposin C (SapC), a heat-stable protein with 80 amino acids, embedded in vesicles of the phospholipid DOPS (Dioleoyl Phosphatidylserine).

BXQ-350 favorably activates multiple enzymes in sphingolipid metabolism

BXQ-350 regulates sphingolipid metabolism by activating multiple enzymes, resulting in lower levels of S1P and increased ceramide levels. S1P promotes cancer cell proliferation, activates oncogenic pathways, and stimulates immuno-suppressor cells promoting a pro-tumoral microenvironment. Higher levels of ceramide in colorectal cancer have been associated with improved survival.

Saposin C

The active ingredient in BXQ-350, Saposin C, is an essential allosteric activator of multiple sphingolipid enzymes and has been shown to increase ceramides and decrease S1-P which may contribute in establishing a beneficial sphingolipid homeostasis in cancers and neurodegenerative diseases.

Addressing Significant Unmet Needs in Standard of Care

Sphingolipid metabolism is disrupted by cancers, functioning as a critical survival pathway for tumor cells while also promoting proliferation, migration angiogenesis, and immune evasion.

Scientific and clinical evidence to date suggests that BXQ-350 has the potential to improve cancer treatment for patients through its monotherapy benefits and in combination with chemotherapeutics. BXQ-350 has demonstrated a reduction in dose-limiting side effects of some chemotherapeutics, allowing for better quality of life with fewer dose reductions.

Low toxicity in combination treatmentScientific and clinical evidence to date suggests that BXQ-350 has the potential to improve cancer treatment for patients through its monotherapy benefits and in combination with chemotherapeutics. BXQ-350 has demonstrated a reduction in dose-limiting side effects of some chemotherapeutics, allowing for better quality of life with fewer dose reductions.

Generally well-tolerated BXQ-350 has shown preliminary safety and tolerability in a Phase 1 clinical trial across several solid tumor types.

Neuroprotective propertiesBXQ-350 has the potential to reduce intensity with delayed onset of neurotoxicities in patients who are actively receiving chemotherapy.

Case Studies

Phase 1 Patient 1080-001: Long Lasting Benefit in mCRC >7 years

40-yr old female with stage 4 metastatic Colorectal Cancer

Diagnosed in Nov 2015, previously treated with surgery, chemotherapy and radiation (>3 lines)

Rapid progression (5 months) prior to starting BXQ-350

Target lesion (1.5 centimeters) remained unchanged per RECIST criteria

Still Stable Disease over 7 years on study

Phase 1 Patient 1008-701: Long Lasting Benefit in GBM > 7 years

Red Arrows indicate the initial target lesion that decreased in size while on study

Blue Arrows indicate new area of enhancement

Note: Surgery in 2018 revealed significant treatment effect with only trace tumor cells present

Phase 1 Patient 1075-213:
Partial Response in Glioblastoma (-74%)

65-yr old female with recurrent Glioblastoma (rGBM)

GBM diagnosed in 2017 (stage IV) previously treated with surgery, chemotherapy and radiation

Rapid progression (2 months) prior to starting BXQ-350 in 2018

1 target lesion (L parietal) 1.4 centimeters at Screening down to 0.36 centimeter at Day 56 (-74%)

Progressed after 948 days on BXQ-350

Interested in learning more about BXQ-350 or Bexion Pharmaceuticals?

Reach out